Table 3. Patients with EGFR mutation who were enrolled in the phase II trial.

No.	Age	Sex	Smoking history	Histology	Stage	Specimen	EGFR mutation site	Nucleotide change	Amino-acid change	Response	TTP (month)	OS (month)
1	47	F	Never	Ad	IV	Surgery	Exon 19	2235–2249 del	del E746-A750	CR	16.8+a	16.8+
2	72	F	Never	Ad	Recurrence	TBB	Exon 19	2237–2254 del	del E746-S752insV	CR	8.3	14.8+
3	68	F	Never	Ad	IV	LB	Exon 19	2236–2250 del	del E746-A750	PR	7.5	14.7+
4	63	F	Former	Sq	IV	TBB	Exon 19	2236–2250 del	del E746-A750	PD	0.5	6.9
5	80	F	Never	Ad	IV	TBB	Exon 19	2236–2250 del	del E746-A750	SD	8.9	13.6+
6	78	M	Current	Ad	Recurrence	Surgery	Exon 21	2573 T>G	L858R	PR	13.4+	13.4+
7	67	F	Never	Ad	IIIb	TBB	Exon 19	2236–2250 del	del E746-A750	PR	12.8+	12.8+
8	65	F	Never	Ad	IV	TBB	Exon 19	2240–2257 del	del L747-P753insS	PR	11.9	11.9+
9	51	F	Never	Ad	IV	TBB	Exon 19	2240–2257 del	del L747-P753insS	PR	11.3	12.7+
10	57	F	Never	Ad	IV	TBB	Exon 19	2240–2257 del	del L747-P753insS	PR	12.7+	12.7+
11	83	F	Never	Ad	Recurrence	Surgery	Exon 21	2573 T>G	L858R	PR	11.7+	11.7+
12	81	F	Never	Ad	IIIb	TBB	Exon 19	2240–2257 del	del L747-P753insS	PR	2.6	7.5+
13	52	F	Never	Ad	IV	TBB	Exon 19	2235–2249 del	del E746-A750	PR	7.1	7.1+
14	70	M	Never	Ad	IV	Surgery	Exon 21	2573 T>G	L858R	PD	1.9	3.1
15	69	F	Never	Ad	Recurrence	Surgery	Exon 19	2236–2250 del	del E746-A750	PR	7.0+	7.0+
16	65	M	Current	Ad	IV	PLB	Exon 19	2236–2250 del	del E746-A750	PD	0.9	5.4+

Abbreviations: TTP=time to progression; OS=overall survival; F=female; M=male; Ad=adenocarcinoma; del=deletion; Sq=squamous cell carcinoma; TBB=transbronchial biopsy; ins=insertion; CR=complete remission; LB=liver biopsy; PR=partial remission; SD=stable disease; PD=progressive disease; PLB=percutaneous lung biopsy; EGFR=epidermal growth factor receptor.

^aStill alive with no progression at the time of data collection.